Pfizer announces completion of Wyeth acquisition

Pfizer has announced that it has successfully completed its acquisition of Wyeth.

The two firms’ operations have now been fully combined, making Pfizer a more diversified healthcare organisation with product offerings in animal, human and consumer health, including biologics, vaccines, small molecules and nutrition across the developed and emerging markets.

Additionally, it now has medicines in numerous burgeoning therapeutic areas, as well as a powerful pipeline and premier scientific and manufacturing capabilities.

Jeffrey Kindler, chairman and chief executive officer of Pfizer, commented: “Pfizer’s newly strengthened company will have some of the best assets, people, pipeline and capabilities in the industry.”

He added that the firm will also benefit from the expertise of “many first-class scientists and business leaders” now that Wyeth has been fully integrated.

In other Pfizer news this week, the company revealed that it has reached an agreement with two subsidiaries of Mylan to establish a license agreement for a generic version of antifungal agent Vfend (voriconazole).